Inspira Technologies reported financial results for the six-month period ended June 30, 2025: - Generated first commercial revenue commitments in April 2025 and secured binding purchase orders totaling $49.5 million for the INSPIRA ART100 system in July and August 2025, including a $22.5 million order and a $27 million order from a national ministry of health in Africa. The company expects to recognize these revenues during 2026. - Total operating expenses increased to $7.235 million for the six months ended June 30, 2025, compared to $5.806 million during the same period in 2024. - Research and development expenses increased to $3.638 million for the six months ended June 30, 2025, from $3.270 million in the same period in 2024. The increase is mainly due to higher personnel and salaries, exchange rate differences, and an increase in share-based compensation. - The HYLA blood sensor demonstrated 97.35% accuracy in clinical validation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-094366), on October 01, 2025, and is solely responsible for the information contained therein.
Comments